Ticker: ALZN

Alzamend Neuro, Inc. (NASDAQ: ALZN) - Quick internal read Snapshot - what's happening inside * Cash position improved to $5,620,872 as of July 31, 2025 (up from $3,948,658 on April 30, 2025). * Company raised $4,035,000 in the quarter from Series C convertible preferred stock financings (net proc...

Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative conditions, particularly Alzheimer's disease. The company reported its financial results for the period ending January 31, 2025, revealing both advancement in R...